Novel adjuvant formulations for delivery of anti-tuberculosis vaccine candidates

详细信息    查看全文

• 作者：Else Marie Agger ^{eag@ssi.dk" class="auth_mail" title="E-mail the corresponding author}
• 关键词：AS ; Adjuvant Systems ; CAF ; cationic adjuvant formulation ; CMI ; cell-mediated immune ; TCM ; central memory T cell ; DDA ; dimethyl dioctadecyl ammonium ; TEM ; effector memory T cell ; FCA ; Freund's complete adjuvant ; GLA ; glucopyranosyl lipid adjuvant ; GRoMM ; MMG ; glycerol monomycolate ; IFN-γ ; interferon-γ ; IL-17 ; interleukin-17 ; LPS ; lipopolysaccharide ; MCL ; macrophage C-type lectin ; MPL ; monophosphoryl lipid A ; MAIT ; mucosa-associated invariant T cells ; MDP ; muramyl dipeptide ; M.tb ; Mycobacterium tu
• 刊名：Advanced Drug Delivery Reviews
• 出版年：2016
• 出版时间：1 July 2016
• 年：2016
• 卷：102
• 期：Complete
• 页码：73-82
• 全文大小：626 K

文摘

There is an urgent need for a new and improved vaccine against tuberculosis for controlling this disease that continues to pose a global health threat. The current research strategy is to replace the present BCG vaccine or boost BCG-immunity with subunit vaccines such as viral vectored- or protein-based vaccines. The use of recombinant proteins holds a number of production advantages including ease of scalability, but requires an adjuvant inducing cell-mediated immune responses. A number of promising novel adjuvant formulations have recently been designed and show evidence of induction of cellular immune responses in humans. A common trait of effective TB adjuvants including those already in current clinical testing is a two-component approach combining a delivery system with an appropriate immunomodulator. This review summarizes the status of current TB adjuvant research with a focus on the division of labor between delivery systems and immunomodulators.